|
|
Speakers 
 Dr Salah Ahmed,
Executive Vice President and Head of Global Research and Development,
Barr Laboratories, Inc
Dr. Salah U. Ahmed is the Executive Vice President and Head of Global Research and Development at Barr Laboratories, Inc. He is responsible for the development of generic and proprietary pharmaceuticals as well as API and biotechnology products. Barr’s product portfolio encompasses diverse Drug Delivery Systems including parenteral, nasal, ocular, oral, transmucosal, transdermal, and intrauterine routes of administration.
The corporation runs it research and development operations in five states in the USA and several countries in Europe and in India.
Dr. Ahmed received his MS in industrial Pharmacy and PhD in Pharmaceutical Sciences from St. Johns University, New York. He has more than a quarter century of pharmaceutical experience, of which 14 years is at Barr Laboratories, Inc. His leadership role in product development has significantly contributed to Barr’s transformation to a specialty pharmaceutical company and a world leader in the generic pharmaceutical industry.
|
Dr Ruth Ben-Yakar Maya,
Vice President of Development and Applications,
Procognia
|
Dr Christopher Bravery,
Pharmaceutical Assessor, Biologicals and Biotechnology Unit,
Medicines and Healthcare Products Regulatory Agency
|
 Dr Crawford Brown,
Chief Executive Officer,
Eden Biodesign
Crawford is CEO of Eden Biodesign (contract development and manufacturing services) and leads Eden Biopharm consulting services now established one of Europe’s largest and most successful specialist biopharmaceutical technical-regulatory consultancies.
In 2004 Eden raised £5m equity capital from an investment syndicate led by Stephens Inc, the largest privately held investment banking firm outside of Wall Street. Additionally, Eden successfully won the European-wide UK government tender to lease and operate the UK National Biomanufacturing Centre a £30 million project sponsored by the North West Development Agency, the European Regional Development Fund and the UK Department of Trade and Industry.
Crawford has been involved with the Biotech sector for over 20 years having held senior positions in product development at Celltech-Medeva Pharma (Liverpool), British Biotech (Oxford) and Wellcome Biotech (Beckenham, Kent). At Medeva, as Director of Product Development, he established one of the UK’s largest product development teams that were the first in the UK to take a recombinant vaccine from the laboratory through to approval by the European Medicines Control Agency (EMEA).
Crawford qualified from Strathclyde University with a BSc in Applied Microbiology and a PhD in Chemical and Process Engineering. He is a Senior Visiting Lecturer on Modular Training for the Bioprocess Industries (MBI) course at the Advanced Centre for Biochemical Engineering. University College, London.
Crawford has completed assignments over the past five years in Denmark, Germany, Switzerland, Netherlands, Australia, India, Japan, South Korea, Taiwan and the USA. The focus of assignments is exclusively biopharmaceutical development including therapeutic and prophylactic vaccines, monoclonal antibodies, gene therapy and stem cell/tissue engineered products.
|
 Dr Aleksandar Danilovski,
Senior Director of Vertical Integration,
Pliva
Dr. Aleksandar Danilovski is the Senior Director and Head of Global API Research and Development at PLIVA, subsidiary of Barr Pharmaceuticals, Inc. He is responsible for the research and development of numerous active pharmaceutical ingredients (APIs or drug substances). His leadership role includes overseeing various aspects of organic and inorganic synthetic chemistry and analytics, scale-up and process development, solid-state chemistry and analytics (polymorphism related phenomena), morphological and surface studies (particle size and shape) up to the final goal of developing vertically integrated formulation (drug product).
Dr. Danilovski received (with honors) his Ph.D. in Chemistry and Crystallography from University of Cambridge, United Kingdom and University of Zagreb, Croatia. He has around fifteen years of experience in the pharmaceutical industry, and quite a number of papers in peer-reviewed scientific journals, poster and oral contributions at various international conferences, as well as a high number of granted patents and patent applications.
|
 Dr Dinesh Dua,
former President of the International and Biotechnology Strategic Unit,
Wockhardt
Dinesh Dua, is the President of Wockhardt Ltd’s International & Biotechnology Strategic Business Unit( SBU).
Mr Dua holds a Masters in Business Management (M.B.A.)-1979 batch from the Indian Institute of Management Ahmedabad. He has over 27 years of professional experience across varied industries such as Healthcare and Pharmaceuticals, Petrochemicals and Consumer goods, having worked in multinational organizations such as Hoechst (Sanofi Aventis) & Berger Paints, and large Indian Corporates like Reliance & Jubilant Organosys. His last assignment was as President at Zydus Cadila Healthcare.
He has also served as a member of various subcommittees of the Confederation of Indian Industry (CII), one of the major Industry Associations of India.He is also a visiting faculty to leading & reputed Management institutes in India.
|
William Haddad,
Chairman and Chief Executive Officer,
Biogenerics, Inc.
|
Dr Peter Kalinka,
Managing Director,
Accelsiors Group International
|
Kate Kuhrt,
Director of Industry Research, Newport Strategies,
Thomson Scientific
Kate Kuhrt is a Director of Industry Research at Newport Strategies, a Thomson Business, where she oversees the company’s research efforts. Newport Strategies provides generics, innovators, and specialty pharmaceutical companies with competitive intelligence on active ingredients and their manufacturers worldwide. Newport’s Horizon GlobalTM system is used by generic companies all over the world to target products for development and to source active ingredients.
Since joining the company in 2002, Ms. Kuhrt has played an integral role in expanding the worldwide network of industry experts with whom Newport works to validate the accuracy of data about APIs and their manufacturers in its systems.
Prior to joining Newport, Ms. Kuhrt was an Associate at the Pharmaceuticals division of CRA International, a business and litigation consulting firm headquartered in Boston, Massachusetts, USA. While at CRA, she worked mostly with multinational pharmaceutical companies, helping to develop their pricing, launch, and managed care strategies. In addition, she frequently contributed to litigation cases involving damages stemming from alleged patent infringement or deals between innovators and generics.
|
 Precious Matsoso,
Director of Technical Cooperation for Essential Drugs,
World Health Organisation, Switzerland
Precious Matsoso is the Director of the Department of Technical Cooperation for Essential Drugs and Traditional Medicines, and has been appointed in this position for over a year. Prior to this she has been the Registrar of Medicines of the National Drug Regulatory Authority in South Africa, the Medicines Control Council. She has been a senior official in the South African Government for eight years and also served as Secretariat of the Southern African Development Community (SADC) harmonization initiative and has coordinated related activities for the region. She has served in various bodies including Medicines Control Council, which she headed for 7 years, She has been a member of the National Research Ethics Council, and directed the Essential Drugs. Programme for the South African Health Department. She has been a member of various advisory panels locally and internationally, mainly tasked with improving access to medicines and antiretrovirals in particular. She has worked in both the public and private sector at management level. She studied pharmacy degree and post graduate diploma in health management in South Africa.
|
Jo Pisani,
Director,
Pricewaterhousecoopers Llp
|
 Bruce Rawlings,
Product Manager, BioPharmaceutical Division,
Pall Life Sciences
Bruce Rawlings is a Product Manager in the BioPharmaceutical division of Pall Life Sciences. During his 12 years at Pall he has worked in Quality Assurance and in Pall’s Scientific and Laboratory Services (SLS) providing technical support & training for Pall’s Biopharmaceutical customers. More recently, Bruce has supported the Pall tangential flow filtration (TFF) products as a Technical & System Specialist, Applications Engineer and Product Manager. He is currently the Product Manager for Single Use Systems, focussing mainly on tangential flow filtration technologies and applications.
Bruce has a Master of Science Degree in Advance Manufacturing Technology and a Bachelor of Engineering Degree, both obtained from Portsmouth University.
|
David Rose,
Partner,
SJ Berwin LLP
|
Theo Savvides,
Partner,
Osborne Clarke
|
 Dr Sunil Shaunak,
Professor of Infectious Diseases, Faculty of Medicine,
Imperial College London
Born in Kenya of Indian extraction, he grew up in London. He studied undergraduate medicine at London University, and postgraduate medicine at Edinburgh and Duke Universities. He received his PhD from Imperial College London. He became a Consultant Physician to Hammersmith Hospital London in 1991 and was awarded the first Personal Chair in Infectious Diseases at Imperial in 2004. He is a Fellow of the Royal Colleges of Medicine, Pathology and Tropical Medicine. Over the last 20 years, his research interests have focused on the discovery and clinical development of new, cost-affordable medicines for AIDS, Hepatitis C and leishmaniasis for use in developing parts of the world. He has published 5 Nature research journal papers and is the inventor of 8 patents. He is the Founder of a Charitable Trust and is the Founder of a University of London Biotechnology spinout company. In the last 3 months, his ideas on “Ethical Pharmaceuticals” have received widespread international coverage in the media. His Imperial website address is http://www1.imperial.ac.uk/medicine/people/s.shaunak/
|
Sally Shorthose,
Partner,
Bird & Bird
|
Dr Anthony So,
Director, Program on Global Health and Technology Access, Terry Sanford Institute of Public Policy,
Duke University
|
 Dr Brian Tempest,
Chief Mentor & Executive Vice Chairman of the Board,
Ranbaxy Laboratories
Dr. Brian Tempest has worked in the pharma industry for the last 36 years. During this time he has worked for several pharma majors, including Glaxo & Searle, around the world and joined Ranbaxy 12 years ago. During this period Ranbaxy has transformed from a small company focused on the India domestic market, to a top 10 global generic company. Dr. Tempest lives in New Delhi, India and has been President, Managing Director & Chief Executive Officer and is presently the Chief Mentor & Executive Vice Chairman of the Board. Dr. Tempest is scheduled to retire from Ranbaxy in 2007, when he reaches 60. Dr. Tempest is one of a few westerners to hold a leadership position in an Indian blue chip MNC, and has a unusual insight into India.
Dr Tempest is also a Honorary Professor of the Management School at Lancaster University, UK, and he sits on the Editorial Board of the Journal of Generic Medicines.
|
 Jonas Tryggvason,
Executive Vice President Marketing and Sales, CEE and Asia,
Actavis
Since December 2005 – Executive Vice President, Actavis Group (CEEA S&M).
2004-2005 – Actavis Eastern Europe Regional Director (Russia, Ukraine & CIS) and Head of Actavis Representative Office in Moscow:
*Unifying diverse representative offices of Actavis Group into one regional team utilizing the synergies and local competence;
*Intensive marketing build up for pharmaceutical products, leading a team of 200 employees in Russia, Ukraine and CIS countries;
*Increased sales in the region by 20% to over USD70 million.
|
 Dr Patrick Vink,
Independent Consultant Life Sciences,
Former Head of Global Biopharmaceuticals at Sandoz
Patrick Vink is a citizen of the Netherlands, who, in addition to his doctorate of Medicine holds a post-doctorate Masters of Business Administration. Starting his professional career in the 80ies he held different marketing positions at the dutch affiliate of the French Pharma company Sanofi until he became general manager Nutricia (a dutch babyfood company) in Hungary. When returning at Sanofi he was appointed as Director global Business Unit Cardiovascular & Thrombosis. After joining Biogen he served as Vice-President Sales International, holding responsibility for commercial operations.
In 2002 he became Global Head Business Unit Biopharmaceuticals at Sandoz. Since leaving Sandoz in 2006 he is an independent advisor in the Life Sciences Industry.
|
Dr Keith Webber,
Deputy Director of the Office of Pharmaceutical Science, Center for Biologics Evaluation and Research,
FDA
|
Tim Wilsdon,
Vice President,
CRA International
|
 Dr Katherine Woo,
Senior Director, Corporate Partnering and Portfolio Development,
Institute for OneWorld Health
|
|
|
|
